Tempus AI, Inc. (NASDAQ:TEM) Director David R. Epstein Sells 370 Shares

Tempus AI, Inc. (NASDAQ:TEM) Director David R. Epstein sold 370 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $53.31, for a total transaction of $19,724.70. Following the transaction, the director now owns 27,524 shares in the company, valued at approximately $1,467,304.44. This trade represents a 1.33 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Tempus AI Trading Up 11.9 %

Tempus AI stock opened at $69.18 on Thursday. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Tempus AI, Inc. has a one year low of $22.89 and a one year high of $79.49. The business has a fifty day moving average of $44.32 and a two-hundred day moving average of $48.73.

Analysts Set New Price Targets

Several research analysts have issued reports on TEM shares. Loop Capital lowered their price objective on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research report on Tuesday, January 14th. TD Cowen restated a “buy” rating and issued a $74.00 price target (up previously from $58.00) on shares of Tempus AI in a research report on Wednesday. Guggenheim initiated coverage on Tempus AI in a research report on Monday, December 9th. They set a “buy” rating and a $74.00 price objective for the company. Stifel Nicolaus lowered Tempus AI from a “buy” rating to a “hold” rating and boosted their target price for the company from $45.00 to $65.00 in a report on Monday, November 11th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $56.00 price target on shares of Tempus AI in a report on Tuesday, January 14th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, Tempus AI has an average rating of “Moderate Buy” and a consensus target price of $58.55.

Institutional Trading of Tempus AI

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. First Horizon Advisors Inc. acquired a new position in Tempus AI during the third quarter worth about $30,000. FNY Investment Advisers LLC acquired a new stake in shares of Tempus AI in the 4th quarter worth approximately $67,000. IFP Advisors Inc purchased a new position in Tempus AI in the 4th quarter valued at approximately $76,000. US Bancorp DE purchased a new stake in Tempus AI during the fourth quarter worth $80,000. Finally, Vestor Capital LLC purchased a new stake in Tempus AI during the third quarter worth $153,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.